These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31710801)

  • 1. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study.
    Jeong JY; Jun DW; Park SJ; Sohn JH; Kim SG; Lee SW; Jeong SW; Kim MY; Kim W; Shim JJ; Kim HS; Suk KT; Ahn SB
    Korean J Intern Med; 2020 Sep; 35(5):1074-1083. PubMed ID: 31710801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
    Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
    World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India.
    Behera MK; Shukla SK; Dixit VK; Nath P; Abhilash VB; Asati PK; Jain AK
    Indian J Med Res; 2018 Aug; 148(2):200-206. PubMed ID: 30381543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
    Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
    [No Abstract]   [Full Text] [Related]  

  • 6. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy.
    Sood A; Midha V; Goyal O
    Ann Hepatol; 2014; 13(5):503-9. PubMed ID: 25152982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
    Carr C; Hollinger FB; Yoffe B; Wakil A; Phillips J; Bzowej N; Leung J; Mirro K; Poordad F; Moore DH; Gish RG
    Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial.
    Yokoyama S; Takahashi S; Kawakami Y; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K
    J Viral Hepat; 2014 May; 21(5):348-56. PubMed ID: 24716637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients.
    Helal GK; Gad MA; Abd-Ellah MF; Mahgoup EM
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):553-7. PubMed ID: 26872109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.
    Esmat G; El Raziky M; Elsharkawy A; Sabry D; Hassany M; Ahmed A; Assem N; El Kassas M; Doss W
    J Interferon Cytokine Res; 2015 Jan; 35(1):49-54. PubMed ID: 25061714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis.
    Kitson MT; Sarrazin C; Toniutto P; Eslick GD; Roberts SK
    J Hepatol; 2014 Dec; 61(6):1247-52. PubMed ID: 25135863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
    Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C.
    Brjalin V; Salupere R; Tallo T; Kuznetsova T; Priimägi L; Tefanova V
    Cent Eur J Public Health; 2012 Jun; 20(2):150-5. PubMed ID: 22966742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.
    Thu Thuy PT; Bunchorntavakul C; Tan Dat H; Rajender Reddy K
    J Hepatol; 2012 May; 56(5):1012-1018. PubMed ID: 22266603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
    Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
    AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
    J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.
    Nguyen MH; Trinh HN; Garcia R; Nguyen G; Lam KD; Keeffe EB
    Am J Gastroenterol; 2008 May; 103(5):1131-5. PubMed ID: 18477343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.